Innate Pharma(US:IPHA) Financial Modeling Prep·2025-11-13 02:00Core Insights - Innate Pharma S.A. is a prominent biotechnology company specializing in therapeutic antibodies for cancer and other diseases, with notable products like Lacutamab and Monalizumab, and strategic partnerships with AstraZeneca and Sanofi [1] Price Target Analysis - The average price target for Innate Pharma's stock has risen from $3.5 to $5 over the last quarter, indicating a positive sentiment among analysts [2][6] - Three months ago, the average price target was $3.5, reflecting a significant increase linked to advancements in clinical trials or new collaborations [3] - A year ago, the average price target was also $3.5, showing stability, but recent developments have led to a more optimistic outlook from some analysts [4] Analyst Perspectives - Analysts have identified a hammer chart pattern, suggesting potential support for the stock after a decline and indicating a possible trend reversal [2][6] - Despite the overall positive trend, analysts from Leerink Partners have set a more conservative price target of $2, indicating differing views on the stock's future [3][6] Future Developments - Investors are advised to monitor upcoming announcements regarding clinical trial results or new partnerships, as these could significantly influence the stock's target price and market perception [5]